The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone health

NRTI-sparing regimens may avoid long-term mitochondrial, bone and renal toxicities and maintain viral suppression. In the RADAR study, 85 antiretroviral-naïve HIV-infected patients were randomized to receive either raltegravir (RAL) (n = 42) or tenofovir/emtricitabine (TDF/FTC) (n = 43), each with r...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-08, Vol.9 (8), p.e106221-e106221
Main Authors: Bedimo, Roger J, Drechsler, Henning, Jain, Mamta, Cutrell, James, Zhang, Song, Li, Xilong, Farukhi, Irfan, Castanon, Rosinda, Tebas, Pablo, Maalouf, Naim M
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Adenine - administration & dosage
Adenine - analogs & derivatives
Adult
AIDS
Antiretroviral agents
Antiretroviral drugs
Biology and Life Sciences
Bone (long)
Bone density
Bone Density - drug effects
Bone mineral density
Bone turnover
CD4 antigen
Chi-square test
Cholesterol
Collagen
Darunavir
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Dual energy X-ray absorptiometry
Effectiveness
Emtricitabine
Epidermal growth factor receptors
High density lipoprotein
HIV
HIV Infections - drug therapy
HIV Infections - metabolism
HIV Infections - pathology
HIV-1
Human immunodeficiency virus
Humans
Lipoproteins (high density)
Long bone
Markers
Medicine and health sciences
Middle Aged
Mitochondria
Motivation
Organophosphonates - administration & dosage
Patients
Pyrrolidinones - administration & dosage
Radar
Raltegravir Potassium
Ritonavir
Statistical tests
Sulfonamides - administration & dosage
Tenofovir
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:NRTI-sparing regimens may avoid long-term mitochondrial, bone and renal toxicities and maintain viral suppression. In the RADAR study, 85 antiretroviral-naïve HIV-infected patients were randomized to receive either raltegravir (RAL) (n = 42) or tenofovir/emtricitabine (TDF/FTC) (n = 43), each with ritonavir-boosted darunavir (DRV/r). Virologic efficacy was assessed at weeks 24 and 48. Bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry (DXA) scan at baseline and week 48, and bone turnover markers (BTM) assessed at weeks 0, 16 and 48. Using an intention-to-treat analysis, 62.5% of RAL subjects and 83.7% of TDF/FTC subjects were responders (VL
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0106221